2 results
Approved WMORecruiting
The main objectives are to understand how clinical markers and biomarkers previously identified in younger and older AD cohorts apply to the extreme elderly (90+ years old) and to identify novel biomarkers linked with resilience to developing…
Approved WMORecruiting
Part 1: dose safety confirmationPrimary: To evaluate the proportion of participants with TRAEs leading to discontinuation within 12 weeks after the first dose of nivolumab plus2 different dose levels of relatlimab (360 mg and 720 mg) in combination…